Journal articles on the topic 'PT Indofarma'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'PT Indofarma.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Paramesti, Aswini, and Yugih Setyanto. "Strategi Komunikasi PT Indofarma Tbk dalam Membangun Kepercayaan Konsumen di Masa Pandemi." Kiwari 1, no. 1 (2022): 62. http://dx.doi.org/10.24912/ki.v1i1.15508.
Full textWahida Basri, Nur, Muh Rum, and Andi Rustam. "Comparison of Financial Performance in Pharmaceutical Industry Companies." Golden Ratio of Finance Management 4, no. 2 (2024): 226–41. http://dx.doi.org/10.52970/grfm.v4i2.459.
Full textSulistyani, Tri, and Neneng Tita Amalya. "Analysis of Financial Performance in Pharmaceutical Industry Sub-Sector Companies in Indonesia for the 2020 – 2022 Period." Transforma Jurnal Manajemen 2, no. 2 (2024): 52–64. http://dx.doi.org/10.56457/tjm.v2i2.128.
Full textPrihatiningrum, Nadia, and Lalu Husni. "Implementasi Penerapan Upah Minimum Kota Mataram Terhadap Pekerja Pada PT. Indofarma Global Medika." Private Law 4, no. 1 (2024): 139–49. https://doi.org/10.29303/prlw.v4i1.3928.
Full textAtiyah Kirana Ropidah and Diana Wiyanti. "Implementasi GCG PT. Indofarma Terkait Kasus Fraud Berdasarkan Permen BUMN No. Per-2/MBU/2023." Bandung Conference Series: Law Studies 5, no. 1 (2025): 233–42. https://doi.org/10.29313/bcsls.v5i1.15996.
Full textKurniati, Eling Ri, and Tryan Adhi Nugroho. "ANALISIS KINERJA KEUANGAN PT. KIMIA FARMA TBK DENGAN PT. INDOFARMA TBK SEBELUM PANDEMI DAN PADA SAAT PANDEMI COVID-19." Medikonis 13, no. 1 (2022): 20–28. http://dx.doi.org/10.52659/medikonis.v13i1.48.
Full textAviariska Primaning Happy. "Kepastian Hukum Dari Akta Keputusan Hasil e-RUPS Studi Kasus pada PT. Indofarma Tbk Tahun Buku 2019." Jurnal Akta Notaris 3, no. 2 (2024): 148–59. https://doi.org/10.56444/aktanotaris.v3i2.2154.
Full textDeni, Muhammad. "Pengaruh Etos Kerja Terhadap Kinerja Karyawan PT Indofarma Global Medika Cabang Palembang." Jurnal Manajemen Kompeten 4, no. 2 (2022): 56. http://dx.doi.org/10.51877/mnjm.v4i2.207.
Full textAwalya, Nabila, Yusnizal Firdaus, and Marieska Lupikawaty. "Analisis Rasio Profitabilitas Untuk Menilai Kinerja Keuangan pada PT Indofarma Tbk." Jurnal Terapan Ilmu Ekonomi, Manajemen dan Bisnis 2, no. 3 (2022): 127–34. https://doi.org/10.5281/zenodo.7473285.
Full textHandayani, Lovinta Valentina, and Mohamad Heykal. "Analisis dan Penilaian Bisnis Perusahaan BUMN di Industri Farmasi: Studi Kasus Kimia Farma dan Indofarma Tahun 2006-2008." Binus Business Review 3, no. 1 (2012): 155. http://dx.doi.org/10.21512/bbr.v3i1.1291.
Full textJunaedi, Junaedi. "PENGARUH CURRENT RATIO, DEBT TO EQUITY RATIO DAN TOTAL ASSET TURNOVER TERHADAP RETURN ON ASSET STUDI PADA PT. INDOFARMA Tbk YANG TERDAFTAR DI BURSA EFEK INDONESIA PERIODE 2015-2019." EKONOMI BISNIS 26, no. 2 (2020): 358–66. http://dx.doi.org/10.33592/jeb.v26i2.1045.
Full textWidyastuti, Indriyana, and Saptani Rahayu. "Akurasi Potensi Memprediksi Kebangkrutan Metode Altman Z-Score Dan Metode Ohlson O-Score." ProBank 3, no. 2 (2018): 1–7. http://dx.doi.org/10.36587/probank.v3i2.369.
Full textWidyastuti, Indriyana, and Saptani Rahayu. "Akurasi Potensi Memprediksi Kebangkrutan Metode Altman Z-Score Dan Metode Ohlson O-Score." ProBank 3, no. 2 (2018): 1–7. http://dx.doi.org/10.36587/probank.v3i2.369.
Full textMuna Jihan, Lintang Woro, and Risma Ajeng. "Analisis Selisih Nilai Tukar dan Transaksi Mata Uang Asing Pada PT Indofarma Tbk dan Entitas Anak." Jurnal Kendali Akuntansi 2, no. 1 (2023): 189–200. https://doi.org/10.59581/jka-widyakarya.v2i1.2045.
Full textNuha, Muhammad Ulin. "Analisis Kinerja Perusahaan Berbasis Balance Scorecard." Jurnal Akuntansi, Manajemen dan Perbankan Syariah 2, no. 3 (2022): 1–13. https://doi.org/10.32699/jamasy.v2i3.2822.
Full textHamida, Wulan, Ine Mayasari, Banter Laksana, and Dadang Hermawan. "Analysis of Optimal Capital Structure in the Pharmaceutical Industry Companies Listed on the Indonesia Stock Exchange." Indonesian Journal of Economics and Management 3, no. 1 (2022): 61–69. http://dx.doi.org/10.35313/ijem.v3i1.3117.
Full textAzzahra, Shafira, Sifa Nuraeni, Risna Haryati, Ruli Mochammad Chaerudin, and Tatiek Ekawati Permana. "ANALISIS KINERJA RASIO PROFITABILITAS PADA PERUSAHAAN MANUFAKTUR SEKTOR FARMASI YANG TERDAFTAR DI BURSA EFEK INDONESIA TAHUN 2019-2022." JURNAL EKONOMI BISNIS DAN MANAJEMEN (EKO-BISMA) 3, no. 2 (2024): 275–84. https://doi.org/10.58268/eb.v3i2.119.
Full textIsmail, Rizky. "Analisis Rasio Keuangan Untuk Menilai Kinerja Keuangan Perusahaan Kimia Farma Tbk dan PT Indofarma Tbk Periode waktu 1 Tahun." J-AKSI : JURNAL AKUNTANSI DAN SISTEM INFORMASI 4, no. 1 (2023): 1–7. http://dx.doi.org/10.31949/jaksi.v4i1.3026.
Full textPudjiani, Meilina, Yusman Syaukat, and Tony Irawan. "Optimum Portfolio Analysis of Black-Litterman Model in The Indonesian Stock Exchange on Consumer Goods Industrial Sector." Winners 21, no. 1 (2020): 27. http://dx.doi.org/10.21512/tw.v21i1.5954.
Full textPrayoga, Dwiputra Pangestu, Setiawan Temy, and Sugiono Arief. "Fraud Analysis at PT Indofarma Indonesia: A Contextual Qualitative Study using the Fraud Hexagon Model." INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH AND ANALYSIS 08, no. 05 (2025): 2253–58. https://doi.org/10.5281/zenodo.15380382.
Full textGlorya Oktavianti, Bernike Trivena N, and Boniface Ata D. "ANALISA LAPORAN KEUANGAN PERUSAHAAN FARMASI TAHUN 2019-2022." Transformasi: Journal of Economics and Business Management 1, no. 4 (2022): 178–92. http://dx.doi.org/10.56444/transformasi.v1i4.279.
Full textRidianto, Rini, Ravika Permata Hati, and Hanafi Siregar. "Pengaruh Pertumbuhan Perusahaan, Return On Investment Dan Earning Per Share Terhadap Harga Saham Pada Pt. Kimia Farma Dan Pt. Indofarma Sebelum Dan Selama Pandemi Covid-19." Measurement Jurnal Akuntansi 18, no. 1 (2024): 121–30. http://dx.doi.org/10.33373/mja.v18i1.6436.
Full textSaputra, Derian, and Anum Nuryani. "Analisis Financial Distress Menggunakan Metode Altman Z-Score pada PT Indofarma Tbk Periode 2013-2022." AMANAH : Jurnal Ilmiah Ilmu Manajemen 2, no. 2 (2024): 92–108. https://doi.org/10.70451/amanah.v2i2.114.
Full textMokoginta, Rena Mustari. "Mengukur Kinerja Keuangan Menggunakan Eva dan Rasio Aktivitas Pada Industri Farmasi Setelah Holding BUMN." ARBITRASE: Journal of Economics and Accounting 4, no. 1 (2023): 23–32. http://dx.doi.org/10.47065/arbitrase.v4i1.1052.
Full textHangline Herlistiana, Pratista, MGS Aritonang, and Tedy Herdiana. "The Effect of Production and Sales on Leverage and Profitability in The JKN Era (State-Owned and Private Pharmaceutical Companies Tbk, Period 2014–2018)." Daengku: Journal of Humanities and Social Sciences Innovation 3, no. 4 (2023): 662–75. http://dx.doi.org/10.35877/454ri.daengku1921.
Full textLinda, Nur, and Sri Hermuningsih. "ANALISIS KINERJA KEUANGAN SEBELUM DAN SESUDAH PEMBENTUKAN HOLDING BUMN FARMASI PADA PT KIMIA FARMA, Tbk dan PT INDOFARMA, Tbk." CAPITAL: Jurnal Ekonomi dan Manajemen 6, no. 2 (2023): 447. http://dx.doi.org/10.25273/capital.v6i2.14488.
Full textSoviatun, Nuria, and Jerry Heikal. "THE CHANGES IN FINANCIAL PERFORMANCE SEGMENTATION USING FINANCIAL RATIOS PHARMACEUTICAL COMPANIES IN INDONESIA." Cerdika: Jurnal Ilmiah Indonesia 3, no. 08 (2023): 828–39. http://dx.doi.org/10.59141/cerdika.v3i08.688.
Full textDesmaniar, Salwa Anisya, Listri Herlina, and Ilham Winar Nugroho. "Pengaruh Current Ratio, Debt to Asset Ratio, dan Total Asset Turnover Terhadap Return on Asset Pada PT IndoFarma (INAF) Tbk Periode 2014-2023." Jurnal Ilmu Sosial, Manajemen, Akuntansi dan Bisnis 5, no. 3 (2024): 550–61. http://dx.doi.org/10.47747/jismab.v5i3.1941.
Full textManossoh, Hendrik, and Joanne Valesca Mangindaan. "DAMPAK PANDEMI COVID-19 TERHADAP HARGA SAHAM PT. INDOFARMA TBK." JMBI UNSRAT (Jurnal Ilmiah Manajemen Bisnis dan Inovasi Universitas Sam Ratulangi). 10, no. 1 (2023): 539–47. http://dx.doi.org/10.35794/jmbi.v10i1.48182.
Full textNoviarty, Helisa, and Yuniarsih Edryani. "DAMPAK PANDEMI COVID-19 TERHADAP PENGUNGKAPAN TANGGUNG JAWAB SOSIAL PADA SEKTOR FARMASI." JAAKFE UNTAN (Jurnal Audit dan Akuntansi Fakultas Ekonomi Universitas Tanjungpura) 10, no. 2 (2021): 11. http://dx.doi.org/10.26418/jaakfe.v10i2.50961.
Full textRosa, Sara Nurdia, Ledia Tereza, Efa Agustina, Yulana Desilfa, and Dian Puji Puspita Sari. "Formation of Optimal Portfolio Using A Single Index in Pharmaceutical Companies." Research in Accounting Journal (RAJ) 4, no. 1 (2023): 19–26. https://doi.org/10.37385/raj.v3i1.1892.
Full textManungkalit, Santa Maria, Dimas Sumitra Danisworo, and Banter Laksana. "Analisis Rasio Profitabilitas untuk Menilai Kinerja Keuangan PT Indofarma (Persero),Tbk." Indonesian Journal of Economics and Management 2, no. 3 (2022): 621–29. http://dx.doi.org/10.35313/ijem.v2i3.3739.
Full textUtami, Ismi Fauzi, and Wuri Widyani Hapsari. "PENERAPAN IDENTITAS VISUAL PERUSAHAAN PT. BIO FARMA (PERSERO) MELALUI DESAIN GRAFIS PADA MEDIA SOSIAL INSTAGRAM." VISWA DESIGN: Journal of Design 3, no. 2 (2023): 122–33. http://dx.doi.org/10.59997/vide.v3i2.1410.
Full textMulatsih, Dyah Ajeng, and Irni Yunita. "ANALISIS KINERJA DAN KESEHATAN KEUANGAN PERUSAHAAN PADA INDUSTRI FARMASI DENGAN METODE DU PONT SYSTEM DAN MODEL ALTMAN Z-SCORE." Jurnal Mitra Manajemen 3, no. 1 (2019): 44–56. http://dx.doi.org/10.52160/ejmm.v3i1.178.
Full textDevi Savira S and Sri Trisnaningsih. "Violation of Accountant Professional Ethics in the Case of PT. Indofarma Tbk." International Journal of Management Research and Economics 3, no. 1 (2024): 36–45. https://doi.org/10.54066/ijmre-itb.v3i1.2551.
Full textFernawati, Amelia Fernawati, and Dhea Lestari Noor Putri. "Analisis Rasio Profitabilitas dan Rasio Aktivitas Sebagai Dasar Penilaian Kinerja Keuangan Pada PT Indofarma (Persero) Tbk Periode Maret 2014-2018." Jurnal Aktiva : Riset Akuntansi dan Keuangan 2, no. 1 (2022): 35–45. http://dx.doi.org/10.52005/aktiva.v2i1.145.
Full textOctavianty, Ellyn, and Muhamad Syahrial. "ANALISIS FUNDAMENTAL TERHADAP KINERJA KEUANGAN UNTUK PENGAMBILAN KEPUTUSAN PEMBELIAN SAHAM PADA PERUSAHAAN BUMN YANG TERDAFTAR DI BEI." JIMFE (Jurnal Ilmiah Manajemen Fakultas Ekonomi) 6, no. 1 (2018): 17–25. http://dx.doi.org/10.34203/jimfe.v6i1.468.
Full textSofyan Marwansyah, Rani Kurniasari, Teni Agustina, and Nurlaela Eva Puji Lestari. "Analisis Evaluasi Kinerja Portofolio Saham dengan Metode Sharpe pada Perusahaan Farmasi." GEMILANG: Jurnal Manajemen dan Akuntansi 5, no. 2 (2025): 271–82. https://doi.org/10.56910/gemilang.v5i2.1965.
Full textDewi, Iriana Kusuma, and Putri Nilam Kencana. "Dampak Pandemi Covid-19 Terhadap Kinerja Perusahaan Farmasi yang terdaftar di BEI." Jurnal Madani: Ilmu Pengetahuan, Teknologi, dan Humaniora 5, no. 1 (2022): 54–67. http://dx.doi.org/10.33753/madani.v5i1.197.
Full text., Susilawati, O. Feriyanto, and Dessy Nurlaelasari. "Pengaruh Perputaran Persediaan dan Perputaran Total Aset Terhadap Profitabilitas Pada PT Indofarma (Persero) Tbk." STAR 14, no. 1 (2022): 22. http://dx.doi.org/10.55916/jsar.v14i1.33.
Full textMadewi, Astuti. "ANALISIS PREDIKSI KEBANGKRUTAN MENGGUNAKAN MODEL ALTMAN Z-SCORE PT. INDOFARMA TBK TAHUN 2020-2022." ECONOMIST: Jurnal Ekonomi dan Bisnis 1, no. 3 (2024): 12–21. https://doi.org/10.63545/economist.v1i3.26.
Full textWahyuni, Liza, and Charoline Cheisviyanny. "Analisis Praktik Corporate Social Responsibility (CSR) Saat Pandemi Covid-19 pada Perusahaan Farmasi." JURNAL EKSPLORASI AKUNTANSI 5, no. 3 (2023): 1065–83. http://dx.doi.org/10.24036/jea.v5i3.794.
Full textRohmah, Siti, Erni Setawati, Pantas P. Pardede, and Mutiara Rahman. "DETERMINAN DETEKSI KECURANGAN LAPORAN KEUANGAN." Jurnal GeoEkonomi 15, no. 1.2024 (2024): 131–40. http://dx.doi.org/10.36277/geoekonomi.v15i1.2024.440.
Full textRahmawati, Ira, and Dini Verdania Latif. "Pengaruh Total Aset Turnover (Tato) Dan Return On Equity(Roe) Terhadap Pertumbuhan Laba (Studi Kasus Pada Perusahaan Sektor Farmasi Yang Terdaftar Di Bursa Efek Indonesia Selama Masa Pandemi Covid -19)." Journal of Economic, Bussines and Accounting (COSTING) 6, no. 2 (2023): 1886–95. http://dx.doi.org/10.31539/costing.v6i2.5371.
Full textFernawati, Amelia Fernawati. "Analisis Rasio Profitabilitas dan Rasio Keuangan Sebagai Dasar Penilaian Kinerja Keuangan Pada PT. Indofarma (Persero) Tbk Periode Maret 2014-2018." Jurnal Aktiva : Riset Akuntansi dan Keuangan 1, no. 3 (2020): 35–45. http://dx.doi.org/10.52005/aktiva.v2i1.50.
Full textHairani, Yuniar Is, and Isnawati Isnawati. "DETERMINAN POTENSI KECURANGAN LAPORAN KEUANGAN DI INDONESIA." Jurnal Riset Akuntansi Aksioma 23, no. 1 (2024): 1–21. http://dx.doi.org/10.29303/aksioma.v23i1.267.
Full textRambe, Muhammad Juang, Wahyu Indah Sari, and Danioko S. Sembiring. "The position of state-owned enterprises: Towards a health sector super holding company paradigm." Proceeding of International Conference on Healthy Living (INCOHELIV) 1, no. 1 (2024): 315–22. http://dx.doi.org/10.24123/incoheliv.v1i1.6586.
Full textAbdurrahman, Abdurrahman, and Aris Munandar. "ANALISIS RASIO KEUANGAN UNTUK MENILAI KINERJA KEUANGAN PERUSAHAAN FARMASI PT. INDOFARMA, Tbk TAHUN 2011 – 2018." MOTIVASI 5, no. 2 (2020): 860. https://doi.org/10.32502/mti.v5i2.2824.
Full textUriawan, Wisnu, and Iwan Permana. "Effect of Return on Assets (ROA) and Leverage Ratio on Company Value of PT. MNC Land Tbk." Journal of Islamic Economics and Business 2, no. 2 (2023): 152–69. http://dx.doi.org/10.15575/jieb.v2i2.22425.
Full textPutri, Berlian Ernita, Nella Yantiana, and Angga Permadi Karpriana. "Penerapan Model Grover dalam Memprediksi Kebangkrutan pada Sektor Farmasi yang Terdaftar di Bursa Efek Indonesia." Manajemen & Bisnis Jurnal 10, no. 2 (2024): 42–54. https://doi.org/10.37303/embeji.v10i2.214.
Full text